Comparing GLP-1 telehealth providers in 2026 means tracking a moving target — pricing changes quarterly, new platforms launch monthly, and the regulatory landscape keeps shifting. This side-by-side breakdown captures the current state across the dimensions that actually matter for your decision.
The Comparison Framework
We evaluate providers across five axes: monthly cost (all-in, no hidden fees), medication type (compounded vs brand-name, semaglutide vs tirzepatide), clinical support (intake rigor, follow-up frequency, dose titration management), speed (intake to medication delivery), and flexibility (pause/cancel policies, billing structure).
Pricing Tier Breakdown
| Tier | Monthly Cost | What You Get | Best For |
|---|---|---|---|
| Value | $146–199/mo | Compounded semaglutide, basic physician oversight, monthly refills | Budget-conscious patients, first-time GLP-1 users |
| Mid-Range | $200–350/mo | Compounded sema or tirz, structured follow-up, dose titration support | Most patients — best balance of cost and clinical quality |
| Premium | $350–500/mo | High-touch clinical support, dietitian access, body composition tracking | Patients wanting maximum clinical support and accountability |
| Brand-Name | $399–1,399/mo | FDA-approved Wegovy or Zepbound, insurance billing available | Patients with insurance coverage or brand-name preference |
The Hidden Cost Variable
Advertised "starting at" prices often apply to the lowest dose tier or require multi-month commitments. Always ask: what's the all-in monthly cost at the maintenance dose (2.4mg semaglutide or 15mg tirzepatide)? That's the number that matters for budgeting.
Compounded vs Brand-Name: The Core Decision
Compounded GLP-1 medications contain the same active ingredient as brand-name versions but are prepared by licensed compounding pharmacies rather than the original manufacturer. They cost 60–80% less but are not FDA-approved as finished products. They are legal when prescribed by a licensed provider and dispensed by a 503A or 503B pharmacy.
Brand-name medications (Wegovy, Zepbound) are FDA-approved, manufactured under standardized conditions, and are the exact formulations used in clinical trials. They cost more, and insurance coverage is inconsistent (30–60% prior auth denial rate on first attempt).
Neither option is inherently "better." Compounded medications are appropriate for most patients. Brand-name is preferred if you have insurance coverage, want exact clinical-trial formulations, or have concerns about compounding pharmacy quality.
What to Ask Before Choosing
Beyond price, three questions separate good providers from mediocre ones. First: what happens at week 4? The best providers schedule a follow-up to assess tolerability and adjust dosing. Providers that prescribe and disappear have higher dropout rates. Second: can I reach someone between appointments? Side effects like persistent nausea, injection-site reactions, or GI issues need timely guidance — not a 3-day email queue. Third: what's the cancellation policy? If you can't cancel online in under 2 minutes, the provider is optimizing for retention, not for you.
Top-Tier Providers Compared
All providers are US-licensed telehealth platforms. Availability varies by state.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.
Injectable semaglutide only. Embody also offers oral tirzepatide gum which is not featured here.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.
⚕️ Compounded medications are not FDA-approved. They are prepared by licensed pharmacies under physician supervision.
Our Methodology
Side by Side Meds scores providers using a weighted rubric: clinical quality (30%), pricing transparency (20%), medication access (15%), patient experience (15%), pharmacy quality (10%), and accountability (10%). We publish our full methodology and update scores quarterly. Affiliate relationships are disclosed but do not influence scoring.
Sources & References
- Wilding JPH, et al. "STEP 1: Semaglutide in Adults with Overweight or Obesity." NEJM. 2021.
- Jastreboff AM, et al. "SURMOUNT-1: Tirzepatide." NEJM. 2022.
- FDA. Compounding and the FDA: Questions and Answers. 2025.
- KFF. Prior Authorization Denial Rates for Obesity Medications. 2025.